VION - Any thoughts?
Am looking to put some money into VION today. Appears to have limited downside and is still at a great price point. Would appreciate any comments. Thanks
Vion Pharmaceuticals, Inc., a development stage company, engages in the development of therapeutics for the treatment of cancer. The company has two small molecule anticancer agents, including CLORETAZINETM (VNP40101M) and Triapine, in clinical development; and other small molecules and a drug delivery system, including KS119W and heterocyclic hydrazones in preclinical development. Its lead product candidate CLORETAZINETM (VNP40101M), which is in Phase II single agent trial, is a sulfonylhydrazine alkylating agent for the treatment of relapsed acute myelogenous leukemia. Triapine is a small molecule that inhibits the enzyme ribonucleotide reductase, and prevents the replication of tumor cells by blocking a critical step in DNA synthesis. Triapine is in Phase II combination trial with gemcitabine in pancreatic cancer. KS119 is an additional cytotoxic (cell-damaging) compound from the sulfonylhydrazine class. Heterocyclic hydrazones are anticancer compounds that have demonstrated potent antitumor effects. It also has one product development program, TAPET (Tumor Amplified Protein Expression Therapy), a drug delivery system using modified Salmonella bacteria, which is designed to deliver anticancer agents directly to solid tumors. Vion Pharmaceuticals has a collaboration agreement with the National Cancer Institute for the clinical development of Triapine.
AI
Market Data 
Markets 
